GlaxoSmithKline Plc’s much-maligned diabetes drug Avandia will be released from restrictions preventing sales to certain patients after U.S. regulators determined new data show the medicine doesn’t raise heart risks.
Oncologist Bhawna Sirohi hurries to the front of a packed seminar room at Mumbai’s Tata Memorial Hospital on a Thursday afternoon in April. Cramming this meeting into her 12-hour workday, she greets more than three dozen breast cancer patients united by the bright scarves covering their bald heads.
Novo Nordisk A/S, the world’s biggest insulin maker, is seeing a rebound in sales of its Victoza diabetes treatment in the U.S. after a few months of flat growth, Chief Financial Officer Jesper Brandgaard said.
A 63-year-old man with Type 1 diabetes received a transplant of insulin-producing cells with the aid of a device that eliminated use of immune-blocking drugs, a potential breakthrough that may lead to safer and more effective procedures to revive weakened organs.